Skip to content

News

OCRF Research Sheds New Light on Ovarian Cancer Metastasis

OCRF Research Sheds New Light on Ovarian Cancer Metastasis

(July 21, 2014) According to research funded in part by OCRF, circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs. This new finding, supported in part by an OCRF Program Project Development Grant to Anil Sood, MD, … Continued

OCRF Research Shows ARID1A is Tumor Suppressor Gene

OCRF Research Shows ARID1A is Tumor Suppressor Gene

(July 8, 2014) Frequent mutations in the ARID1A gene have been previously discovered in ovarian endometrioid and clear-cell cancers.  Now research supported by OCRF has provided direct evidence that it is an authentic tumor suppressor gene using a mouse model.  OCRF Ann Schreiber Mentored Investigator grantee Bin Guan, PhD is first author, and OCRF Scientific … Continued

Q&A with OCRF Grantee John Weroha, MD, PhD

Q&A with OCRF Grantee John Weroha, MD, PhD

Q&A with John Weroha, MD, PhD 2014 Liz Tilberis Early Career Award Mayo Clinic               Were you always in interested in science?  By the time I was in high school I knew I wanted to have a career in biology, but I think my interest actually started earlier.  When … Continued

No Link Between Fertility Drugs and Breast, Ovarian and Ute...

No Link Between Fertility Drugs and Breast, Ovarian and Uterine Cancers

(July 1, 2014)  There is “little evidence” that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and gynecological cancers, according to the results of a significant 30-year follow-up study. However, the extended use of clomiphene citrate was associated with a higher risk … Continued

Palliative Care at Time of Cancer Diagnosis Improves Survival

Palliative Care at Time of Cancer Diagnosis Improves Survival

(June 25, 2014) Research presented at the annual meeting of the American Society of Clinical Oncology earlier this month suggests that palliative care delivered at the time of cancer diagnosis improves survival. A randomized trial of palliative oncology care in 207 patients with advanced cancer and their caregivers showed that the risk of death at … Continued

Gemcitabine, Carboplatin, and Bevacizumab Extend PFS

Gemcitabine, Carboplatin, and Bevacizumab Extend PFS

(June 24, 2014) Earlier this month, researchers reported results of a Phase II trial which looked at efficacy and safety of a biweekly gemcitabine, carboplatin, and bevacizumab combination in patients with platinum-sensitive recurrent ovarian, peritoneal, or tubal cancer. The results, which were published online June 5, 2014 in the journal Gynecologic Oncology, showed that biweekly … Continued

Webinar Highlights Research News from ASCO

Webinar Highlights Research News from ASCO

On Monday, June 16, 2014, Dr. Douglas Levine of Memorial Sloan Kettering Cancer Center presented a free webinar focusing on research  news that was presented at 2014’s medical meetings.  In his hour-long presentation, he focused primarily on new ovarian cancer research that was presented at the American Society of Clinical Oncology’s annual meeting, which took … Continued

Report from the 2014 American Society of Clinical Oncology ...

Report from the 2014 American Society of Clinical Oncology Annual Meeting

Promising new combination treatments for ovarian cancer Dr. Joyce Liu, MD, on behalf of researchers from the National Cancer Institute (NCI) and Dana Farber Cancer Institute (DFCI), presented striking results from a Phase II trial testing the combination of the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib (which blocks tumors from creating new blood … Continued

2014 ASCO Research Round-Up

2014 ASCO Research Round-Up

Posted by Laura Koontz on June 5, 2014 The 50th Annual Conference of the American Society of Clinical Oncology, held May 30 – June 3 in Chicago, featured a number of promising and thought provoking studies on ovarian cancer. Below is a brief summary of the most notable studies from the meeting. In the coming weeks, we’ll also post … Continued

ASCO News: Two New Drugs Show Promise for Recurrent Ovarian...

ASCO News: Two New Drugs Show Promise for Recurrent Ovarian Cancer

(June 4, 2014) In a study presented at the American Society of Clinical Oncology annual meeting last week, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent ovarian cancer from worsening for almost nine months longer than treatment with olaparib alone. For this study, 90 women with recurrent ovarian cancer that was … Continued

FDA Seeking Comments on Olaparib by June 11

FDA Seeking Comments on Olaparib by June 11

The Food and Drug Administration is seeking comments by June 11, 2014 on its review for Olaparib approval. Olaparib is an oral poly ADP-ribose polymerase (PARP) inhibitor that exploits DNA repair pathway deficiencies to preferentially kill cancer cells.  AstraZeneca, the company that manufactures the drug, has submitted an application to the FDA for approval of … Continued

Breastfeeding, Birth Control Pills May Reduce Ovarian Cance...

Breastfeeding, Birth Control Pills May Reduce Ovarian Cancer Risk Among Women with BRCA Gene Mutations

(May 16, 2014) Breastfeeding, tubal ligation – also known as having one’s “tubes tied” – and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive analysis from a team at the University of Pennsylvania’s Basser Research Center for BRCA. The Basser Research Center for … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.